I decided to rename this category "developing" as opposed to the mature investments we considered earlier. This section covers five Australian funds and stocks. The first two are in this post. Graphs are all in Australian Dollars.
First Sentier Imputation Fund: We now have 1.6% of net worth in this fund. This is the last remaining investment in an account, which was once my core investment. The fund aims to combine long-term capital growth with tax-effective income by targeting Australian growth companies with a high level of franked dividends. It aims to outperform the S&P/ASX 300 Accumulation Index over rolling three year periods before fees and taxes.
The fund has consistently outperformed its benchmark:
Our IRR is 16%. The only downside of this fund is that the unlisted unit trust structure is not very tax efficient, as all gains are paid out in distributions. An alternative is Wilson Asset Management's Leaders Fund (WLE.AX), which is more tax efficient. We have held that for a while in the past but ended up selling to raise cash for other investments. It has done better over three and five years than FS Imputation but much worse in the last year.
This was one of my earliest investments but then I didn't hold any for 20 years until 2021 when I began to consolidate other funds in the account into it. Distributions gradually pay back our investment.
Cadence Opportunities Fund (CDO.AX): 2.5% of net worth. IRR is only 3.5%. It is a long-biased listed Australian equity hedge fund. I recently consolidated my investment in sister fund CDM.AX into this one.
CDO has more flexibility to quickly trade in and out of positions. Initially, the fund did extremely well. Then it became practically a twin of CDM. However, recently it has again begin to diverge in a positive way from CDM. It's not really doing well though. It's still way below the 2022 peak, unlike CFS Imputation above. Unless it starts to do a lot better soon, I don't think there is a good reason to hold it.
No comments:
Post a Comment